IMpassion130
IMpassion130 was the first immunotherapy success in breast cancer, later undermined when a sister trial failed and the approval was withdrawn.
PFS benefit in PD-L1+ (SP142) patients; OS 25.4 vs 17.9 months in PD-L1+ but not statistically tested. IMpassion131 (with paclitaxel) was negative, leading to US withdrawal in 2021. A lesson in chemotherapy partner and biomarker assay choice.
- Median 7.5 vs 5 months with Atezolizumab + nab-paclitaxel compared with Placebo + nab-paclitaxel; about 2.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62, likely range 0.49 to 0.78).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 25.4 vs 17.9 months with Atezolizumab + nab-paclitaxel compared with Placebo + nab-paclitaxel; about 7.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 33 percent lower chance of the event at any given time (hazard ratio 0.67, likely range 0.53 to 0.86).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Median 21 vs 18.7 months with Atezolizumab + nab-paclitaxel compared with Placebo + nab-paclitaxel; about 2.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 13 percent lower chance of the event at any given time (hazard ratio 0.87, likely range 0.75 to 1.02).
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Not significant.
- These results apply to the people the trial enrolled: First-line metastatic TNBC: atezolizumab + nab-paclitaxel. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
902 participants enrolled.
Not formally tested under the hierarchical design
SourceNot significant
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival, PD-L1+ (SP142 IC ≥1%)primary | Atezolizumab + nab-paclitaxel | 185 | 7.5 months | 0.62 (0.49–0.78) | <0.001 | link |
| Placebo + nab-paclitaxel | 184 | 5 months | ||||
| Overall survival, PD-L1+ | Atezolizumab + nab-paclitaxel | — | 25.4 months | 0.67 (0.53–0.86) | — | link |
| Placebo + nab-paclitaxel | — | 17.9 months | ||||
| Overall survival, ITT | Atezolizumab + nab-paclitaxel | — | 21 months | 0.87 (0.75–1.02) | — | — |
| Placebo + nab-paclitaxel | — | 18.7 months |
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-355
Shares IMpassion131, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).
- TrialIZABRIGHT-Breast01
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).
- TrialASCENT-03
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast02
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).
- TrialBEATcc / ENGOT-Cx10 / GOG-3030
Shares Atezolizumab, Paclitaxel / nab-paclitaxel.
- TrialASCENT
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).
- TrialOptimICE-pCR (A012103)
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast05
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Triple-negative breast cancer (TNBC).